Haemonetics Corp
NYSE:HAE
Intrinsic Value
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. [ Read More ]
The intrinsic value of one HAE stock under the Base Case scenario is 87.28 USD. Compared to the current market price of 87.66 USD, Haemonetics Corp is Fairly Valued.
Valuation Backtest
Haemonetics Corp
Run backtest to discover the historical profit from buying and selling HAE stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Haemonetics Corp
Current Assets | 765m |
Cash & Short-Term Investments | 194m |
Receivables | 211.6m |
Other Current Assets | 359.4m |
Non-Current Assets | 1.4B |
PP&E | 318.7m |
Intangibles | 984.3m |
Other Non-Current Assets | 132.5m |
Current Liabilities | 261.8m |
Accounts Payable | 56.8m |
Accrued Liabilities | 58.8m |
Other Current Liabilities | 146.1m |
Non-Current Liabilities | 995.4m |
Long-Term Debt | 856.8m |
Other Non-Current Liabilities | 138.5m |
Earnings Waterfall
Haemonetics Corp
Revenue
|
1.3B
USD
|
Cost of Revenue
|
-590.8m
USD
|
Gross Profit
|
679.3m
USD
|
Operating Expenses
|
-480m
USD
|
Operating Income
|
199.3m
USD
|
Other Expenses
|
-72.8m
USD
|
Net Income
|
126.5m
USD
|
Free Cash Flow Analysis
Haemonetics Corp
HAE Profitability Score
Profitability Due Diligence
Haemonetics Corp's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Haemonetics Corp's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
HAE Solvency Score
Solvency Due Diligence
Haemonetics Corp's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Haemonetics Corp's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HAE Price Targets Summary
Haemonetics Corp
According to Wall Street analysts, the average 1-year price target for HAE is 107.68 USD with a low forecast of 88.88 USD and a high forecast of 126 USD.
Ownership
HAE Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HAE Price
Haemonetics Corp
Average Annual Return | 5.48% |
Standard Deviation of Annual Returns | 42.81% |
Max Drawdown | -69% |
Market Capitalization | 4.5B USD |
Shares Outstanding | 50 786 100 |
Percentage of Shares Shorted | 6.1% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.
Contact
IPO
Employees
Officers
The intrinsic value of one HAE stock under the Base Case scenario is 87.28 USD.
Compared to the current market price of 87.66 USD, Haemonetics Corp is Fairly Valued.